Related Experiment Video
Updated: May 22, 2026
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph
M V Yigit1, S K Ghosh, M Kumar
1Department of Radiology, Molecular Imaging Laboratory, Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.
Abstract:
Metastases, and not the primary tumor from which they originate, are the main reason for mortality from carcinoma. Although the molecular mechanisms behind metastasis are poorly understood, it is clear that epigenetic dysregulation at the level of microRNA expression is a key characteristic of the metastatic process that can be exploited for therapy. Here, we describe an miRNA-targeted therapeutic approach for the prevention and arrest of lymph node metastasis. Therapy relies on the inhibition of the pro-metastatic microRNA-10b. It is delivered to primary and lymph node metastatic tumor cells using an imaging-capable nanodrug that is designed to specifically home to these tissues. Treatment of invasive human breast tumor cells (MDA-MB-231) with the nanodrug in vitro downregulates miR-10b and abolishes the invasion and migration of the tumor cells. After intravenous delivery to mice bearing orthotopic MDA-MB-231-luc-D3H2LN tumors, the nanodrug accumulates in the primary tumor and lymph nodes. When treatment is initiated before metastasis to lymph nodes, metastasis is prevented. Treatment after the formation of lymph node metastases arrests the metastatic process without a concomitant effect on primary tumor growth raising the possibility of a context-dependent variation in miR-10b breast oncogenesis.
Insights
A novel nanodrug targets microRNA-10b to prevent and halt breast cancer lymph node metastasis. This therapeutic approach inhibits the pro-metastatic microRNA-10b, offering a new strategy for cancer treatment.
Area of Science:
- Oncology
- Nanotechnology
- Epigenetics
Background:
- Metastasis, not primary tumors, causes most cancer mortality.
- Epigenetic dysregulation of microRNA expression is crucial in metastasis.
- MicroRNA-10b (miR-10b) is identified as a pro-metastatic factor.
Purpose of the Study:
- To develop and evaluate an miRNA-targeted nanodrug therapy for preventing and arresting lymph node metastasis.
- To investigate the efficacy of inhibiting miR-10b using a targeted nanodelivery system.
Main Methods:
- Development of an imaging-capable nanodrug for specific delivery to tumor tissues.
- In vitro treatment of human breast cancer cells (MDA-MB-231) to assess miR-10b downregulation and effects on invasion/migration.
- In vivo studies in mice with orthotopic tumors to evaluate nanodrug accumulation, metastasis prevention, and therapeutic arrest of lymph node metastases.
Main Results:
- The nanodrug successfully downregulated miR-10b in vitro, inhibiting cancer cell invasion and migration.
- In vivo, the nanodrug localized to primary tumors and lymph nodes.
- Pre-metastasis treatment prevented lymph node metastasis; post-metastasis treatment arrested the process without affecting primary tumor growth.
Conclusions:
- Targeted inhibition of miR-10b using a nanodrug is a viable strategy for preventing and arresting breast cancer lymph node metastasis.
- The nanodrug demonstrates specific accumulation in metastatic sites.
- Findings suggest a context-dependent role for miR-10b in breast oncogenesis, warranting further investigation.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...